We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
The current JANX market cap is 1.84B. The company's latest EPS is USD -1.1673 and P/E is -26.60.
| Quarter End | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 2.46M | 1.25M | 8.9M | 439k | 0 |
| Operating Income | -16.14M | -20.16M | -13.82M | -35.84M | -29.02M |
| Net Income | -11.76M | -14.76M | -5.96M | -28.06M | -20.22M |
| Year End 31 December 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 0 | 3.64M | 8.61M | 8.08M | 10.59M |
| Operating Income | -4.84M | -32.93M | -67.09M | -72.98M | -98.85M |
| Net Income | -6.78M | -32.67M | -63.06M | -58.29M | -68.99M |
| Quarter End | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 380.41M | 688.98M | 691.41M | 695.02M | 1.06B |
| Total Liabilities | 36.06M | 33.22M | 33.74M | 38.92M | 38.74M |
| Total Equity | 344.35M | 655.76M | 657.68M | 656.1M | 1.02B |
| Year End 31 December 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 16.22M | 379.82M | 364.01M | 380.41M | 1.06B |
| Total Liabilities | 9.23M | 13.5M | 43.27M | 36.06M | 38.74M |
| Total Equity | -14.64M | 366.33M | 320.74M | 344.35M | 1.02B |
| Quarter End | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -50.58M | -14.84M | -24.86M | -27.09M | -43.81M |
| Investing | -41.19M | -113.74M | -304.62M | -291.95M | -258.02M |
| Financing | 59.55M | 322.17M | 324.94M | 326.59M | 713.24M |
| Year End 31 December 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -4.37M | -16.98M | -42.92M | -50.58M | -43.81M |
| Investing | N/A | -340.96M | 58.27M | -41.19M | -258.02M |
| Financing | 11.52M | 386.52M | 500k | 59.55M | 713.24M |
| Market Cap | 1.84B |
| Price to Earnings Ratio | -26.60 |
| Price to Sales Ratio | 173.37 |
| Price to Cash Ratio | 4.26 |
| Price to Book Ratio | 1.79 |
| Dividend Yield | - |
| Shares Outstanding | 59.11M |
| Average Volume (1 week) | 642.99k |
| Average Volume (1 Month) | 1M |
| 52 Week Change | -34.26% |
| 52 Week High | 71.71 |
| 52 Week Low | 22.52 |
| Spread (Intraday) | 7.4 (22.77%) |
| Company Name | Janux Therapeutics Inc |
| Address |
corporation trust center wilmington, delaware 19801 |
| Website | https://www.januxrx.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
